2019 half-year inventory: the golden period of the pharmaceutical industry has passed, and medical s

2019-08-02 00:00

In the past decade, driven by the government's increased investment in the medical and health industry, China's medical and health market has experienced a rapid development stage. With the continuous medical reform, the pattern of China's medical market will have fundamental changes. Qingke research center believes that in the future the pharmaceutical industry as a whole will maintain a rapid growth, but the structure will be more optimized. Since the launch of the new medical reform, governments at all levels have increased investment in the construction of medical facilities and equipment upgrading, coupled with the steady increase in the volume of medical services in China, the medical device market in China has ushered in an era of rapid development. To fundamentally solve the problem of raising the price of medical services with medicine will be forced to raise the price of medical services, strong demand and favorable policies will promote the rapid growth of the medical service industry, and mobile medical services will drive the development of medical services and related medical devices.


The golden age of the pharmaceutical industry has passed, and the policy dividend is the key


With the continuous promotion of population aging, disease spectrum change and drug use upgrading, the medium and long term growth trend of the biomedical industry remains unchanged. However, in the short and medium term, the cost control of medical insurance, price reduction through bidding, administrative price reduction, and efficiency of new drug approval have more profound impacts on the development of the industry. Although the national regulatory policies on the pharmaceutical industry are complex and changeable, the industry trends guiding the policy changes are still relatively clear, such as strengthening the rationality of drug use, encouraging the import substitution of high-volume generic drugs, and optimizing the competitive pattern of the industry through the priority review of urgently needed generic drugs.


Good policy & market demand, medical equipment into the fast track of development


Since the launch of the new healthcare reform in 2009, governments at all levels have increased investment in the construction of medical facilities and equipment upgrading, and the steady increase in the volume of medical services in China has ushered in an era of rapid development in the Chinese medical device market. With the improvement of relevant laws and regulations, the policy orientation of Chinese government directors in the medical device industry has become clearer, that is, to gradually improve the regulatory efficiency, encourage innovation, especially domestic key innovation, and enhance quality and safety.


Medical services are the focus of the reform, and mobile medical services will drive the development of related industries


The big advantage in the process of medical reform is the privatization (namely the restructuring of public hospitals), and the medical service will continue to benefit from the system dividend brought by the industry reform in this long period. At present, medical service occupies a relatively low proportion in the overall medical and health industry, and there is basically no policy resistance. The policy environment is better than that of the pharmaceutical industry, and the future space is huge. Under the high growth trend of mobile medical market, the evolution from horizontal application to vertical solution of mobile medical service value chain will become the development direction of the industry.